Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | FKBP1A | P62942 | 3/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | PEPD | P12955 | 2/20 | 0.40 |
| ▸ | XPNPEP1 | Q9NQW7 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | MMP2 | P08253 | 1/20 | 0.39 |
| ▸ | ANPEP | P15144 | 1/20 | 0.39 |
| ▸ | LTA4H | P09960 | 2/20 | 0.38 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4109077 | 1.00 | POLB (0.49) | POLBFKBP1ASMN1; SMN2PEPDXPNPEP1 | |
| SCHEMBL389987 | 1.00 | POLB (0.49) | POLBFKBP1ASMN1; SMN2PEPDXPNPEP1 | |
| Hydrochloric Acid SCHEMBL3055388 | 0.98 | POLB (0.47) | POLBFKBP1ASMN1; SMN2PEPDXPNPEP1 | |
| Hydrochloric Acid SCHEMBL2337448 | 0.98 | POLB (0.47) | POLBFKBP1ASMN1; SMN2PEPDXPNPEP1 | |
| Hydrochloric Acid SCHEMBL5159954 | 0.98 | POLB (0.47) | POLBFKBP1ASMN1; SMN2PEPDXPNPEP1 | |
| SCHEMBL28937243 | 0.94 | FKBP1A (0.49) | POLBFKBP1ASMN1; SMN2TP53MMP2 | |
| SCHEMBL21616613 | 0.94 | FKBP1A (0.49) | POLBFKBP1ASMN1; SMN2TP53MMP2 | |
| SCHEMBL8385960 | 0.80 | POLB (0.36) | POLB | |
| SCHEMBL678254 | 0.80 | POLB (0.36) | POLB | |
| SCHEMBL14048826 | 0.79 | POLB (0.32) | POLBSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 117 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112010914-B | Glucosamine modified pentacyclic piperazine dione and preparation and application thereof | 首都医科大学 | 2023-06-27 | — | — | CN | claimed |
| CN-112010937-B | YIGSR modified pentacyclic piperazinedione and preparation and application thereof | 首都医科大学（CN） | 2023-01-13 | — | — | CN | claimed |
| CN-112010914-A | Glucosamine-modified pentacyclic piperazinedione and preparation and application thereof | 首都医科大学 | 2020-12-01 | — | — | CN | claimed |
| CN-112010930-A | RGD modified pentacyclic piperazinedione and preparation and application thereof | 首都医科大学 | 2020-12-01 | — | — | CN | claimed |
| CN-112010937-A | YIGSR modified pentacyclic piperazinedione and preparation and application thereof | 首都医科大学 | 2020-12-01 | — | — | CN | claimed |
| CN-111995658-A | LDV (laser direct structuring) modified pentacyclic piperazinedione and preparation and application thereof | 首都医科大学 | 2020-11-27 | — | — | CN | claimed |
| CN-105175491-B | A kind of polypeptide NS3 serpin and its preparation method and application containing hydroxyproline skeleton | 山东大学 | 2019-01-11 | — | — | CN | claimed |
| EP-4741399-A1 | LINCOSAMIDE ANTIBIOTICS AND USES THEREOF | President And Fellows Of Harvard College (US) | 2026-05-13 | — | — | EP | disclosed |
| US-20260001924-A1 | NEMO COILED COIL MIMICS AND METHODS OF USING SAME | NEW YORK UNIVERSITY (US) | 2026-01-01 | — | — | US | disclosed |
| EP-3664799-B1 | LINCOSAMIDE ANTIBIOTICS AND USES THEREOF | HARVARD COLLEGE (US) | 2025-10-01 | — | — | EP | disclosed |
| US-12371461-B2 | Nemo coiled coil mimics and methods of using same | NEW YORK UNIVERSITY (US) | 2025-07-29 | — | — | US | disclosed |
| US-20240190930-A1 | NEMO COILED COIL MIMICS AND METHODS OF USING SAME | UNIV NEW YORK (US) | 2024-06-13 | — | — | US | disclosed |
| US-11891422-B2 | NEMO coiled coil mimics and methods of using same | NEW YORK UNIVERSITY (US) | 2024-02-06 | — | — | US | disclosed |
| US-5631385-A | Method for the preparation of N-substituted 4-ketoproline derivatives | DEGUSSA AKTIENGESELLSCHAFT (DE) | 1997-05-20 | — | — | US | disclosed |
| EP-0618810-A4 | BRADYKININ ANTAGONIST PEPTIDES. | SCIOS NOVA INC (US) | 1994-12-07 | — | — | EP | disclosed |
| EP-0618810-A1 | BRADYKININ ANTAGONIST PEPTIDES | SCIOS NOVA INC. (US) | 1994-10-12 | — | — | EP | disclosed |
| EP-0618809-A1 | BRADYKININ TYPE PEPTIDES | SCIOS NOVA INC. (US) | 1994-10-12 | — | — | EP | disclosed |
| EP-0618809-A4 | BRADYKININ TYPE PEPTIDES. | SCIOS NOVA INC (US) | 1994-07-28 | — | — | EP | disclosed |
| WO-1992018156-A1 | BRADYKININ ANTAGONIST PEPTIDES | NOVA TECHNOLOGY LIMITED PARTNERSHIP (US) | 1992-10-29 | — | — | WO | disclosed |
| WO-1992018155-A1 | BRADYKININ TYPE PEPTIDES | NOVA TECHNOLOGY LIMITED PARTNERSHIP (US) | 1992-10-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12371461-B2 | Nemo coiled coil mimics and methods of using same | COIL, CALCOCO2, NCAPH | POLB 2725/4885FKBP1A 2884/4885SMN1; SMN2 346/4885 |
| US-20260001924-A1 | NEMO COILED COIL MIMICS AND METHODS OF USING SAME | DDX21, PHAX, RBX1 | POLB 2834/4885FKBP1A 2912/4885SMN1; SMN2 1850/4885 |
| US-11891422-B2 | NEMO coiled coil mimics and methods of using same | COIL, CALCOCO2, NCAPH | POLB 2725/4885FKBP1A 2884/4885SMN1; SMN2 346/4885 |
| US-20240190930-A1 | NEMO COILED COIL MIMICS AND METHODS OF USING SAME | COIL, CALCOCO2, NCAPH | POLB 2596/4885FKBP1A 2754/4885SMN1; SMN2 352/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.